Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company that reports a focus on advancing immuno-oncology technologies for difficult to treat cancers. Company news and press releases center on the development of its DNase-based oncology platform, which is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs) involved in cancer progression.
News items for XBIO commonly cover preclinical and translational data from its systemic recombinant human DNase I programs, including the systemic DNase I candidate XBIO-015 in combination with CAR T-cell therapies for hematologic and solid tumors. Updates have described studies conducted with academic collaborators showing that co-administration of DNase I with CAR-T cells can reduce tumor burden, decrease metastatic lesions and extend survival in certain cancer models, while enhancing T-cell infiltration and addressing an immunosuppressive tumor microenvironment.
Another recurring theme in Xenetic’s news flow is collaboration and clinical strategy. The company has announced expanded research and development collaborations with The Scripps Research Institute and a Clinical Trial Services Agreement with PeriNess Ltd. News releases describe exploratory, investigator-initiated clinical studies of systemic DNase I in combination with FOLFIRINOX for unresectable, locally advanced or metastatic pancreatic cancer, and in combination with anti-CD19 CAR T cells in large B cell lymphoma, as well as exploratory plans in osteosarcoma, Ewing sarcoma and colorectal cancer models.
Investors following XBIO news will also find quarterly financial results, details of underwritten offerings conducted under a shelf registration statement, and updates related to annual stockholder meetings and proxy materials. Together, these items provide insight into Xenetic’s progress in advancing its DNase platform toward Phase 1 clinical development, its collaboration-driven development model and its capital-raising activities. Bookmarking this page allows readers to review the sequence of scientific, clinical, financial and corporate announcements directly from the company’s public communications.
Xenetic Biosciences (NASDAQ: XBIO) reported significant developments in its annual results for 2022. The company is focusing on the DNase oncology platform, which targets neutrophil extracellular traps to improve cancer therapies. The DNase program is progressing towards Phase 1 clinical development and aims to provide treatments for pancreatic carcinoma and other solid tumors. The year ended with approximately $13.1 million in cash. Financially, the net loss for 2022 was $6.6 million, with a 50.8% increase in research and development expenses. A royalty payment of $1.7 million was received from a sublicense with Takeda, marking a 47.1% year-over-year increase.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced participation in the Virtual Investor NETs in Cancer Spotlight Event on March 29, 2023, at 11:00 AM ET. CEO Jeffrey Eisenberg, CSO Curtis Lockshin, and oncology leader Dr. Jonathan Spicer will discuss the Company's DNase-based oncology platform and the role of Neutrophil Extracellular Traps (NETs) in cancer. The event will feature a moderated roundtable discussion, enabling investors to submit questions live. A live video webcast will be available on Xenetic's website and archived for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) announced that the Canadian Intellectual Property Office has issued a notice of allowance for Patent Application No. 3,001,543, titled Method to Improve Safety and Efficacy of Anti-Cancer Therapy. This patent application aims to improve treatments for cancer patients by using a DNase enzyme to mitigate chemotherapy-associated side effects. CEO Jeffrey Eisenberg emphasized the company's commitment to advancing its DNase platform and strengthening its intellectual property portfolio. The approved patent enhances Xenetic's capabilities in the oncology sector, specifically targeting pancreatic carcinoma and other difficult-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) will present at the Virtual Investor 2023 Companies to Watch Event on January 17, 2023, at 10:00 AM ET. CEO Jeffrey Eisenberg will showcase the company's advancements in immune-oncology technologies aimed at treating hard-to-treat cancers. A live video webcast will be available on the company's Investors website page, with a replay accessible for 90 days post-event. Xenetic specializes in DNase platforms for cancer treatment and the XCART™ technology for personalized CAR T therapies.
Xenetic Biosciences (NASDAQ:XBIO) announced the appointment of Dr. Jonathan Spicer to its Scientific Advisory Board, enhancing its expertise in the role of neutrophil extracellular traps (NETs) in cancer biology. Dr. Spicer, an expert in neoadjuvant immunotherapy for lung cancer, will support the advancement of the Company's DNase platform, which aims to improve cancer treatment outcomes by targeting NETs. This collaboration is pivotal as Xenetic progresses towards a planned Phase 1 study, indicating potential growth in its innovative oncology technologies.
Xenetic Biosciences (NASDAQ: XBIO) reported its financial results for Q3 2022, highlighting progress in its DNase-based oncology platform targeting hard-to-treat cancers. The company ended the quarter with $13.8 million in cash. Notably, net loss was approximately $0.8 million, with R&D expenses down 48.9% to $0.4 million. The company also received $0.4 million in royalties, reflecting an 18.6% increase year-over-year. Xenetic remains focused on advancing its DNase program and collaborations aimed at enhancing cancer therapies.
Xenetic Biosciences (NASDAQ: XBIO) announced the signing of a patent assignment from CLS Therapeutics as part of a collaboration with CLS and VolitionRx (NYSE AMERICAN: VNRX) to develop NETs-targeted adoptive cell therapies for cancer. In exchange for the patent, Xenetic will issue 850,000 shares to CLS. This collaboration aims to combine Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform, targeting various solid tumors where current therapies are ineffective. The partnership will also share proceeds from any resulting commercial products.
Xenetic Biosciences (NASDAQ: XBIO) announced the appointment of Allan Tsung, MD to its Scientific Advisory Board. Dr. Tsung, a leading expert in cancers of the liver, bile duct, and pancreas, brings extensive clinical and research experience, aiming to guide the company’s DNase-based oncology platform. His leadership at the University of Virginia and participation in numerous academic surgical organizations positions him to contribute significantly to Xenetic’s development strategies. This appointment is part of the company’s commitment to advancing innovative immune-oncology technologies to address unmet medical needs in cancer treatment.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY, from September 12-14, 2022. Jeffrey F. Eisenberg, the CEO, will present at the event, which will also feature virtual one-on-one meetings for registered investors. A video webcast of the presentation will be available on-demand starting September 12 at 7:00 AM ET, archived for 90 days. The Company is advancing innovative immune-oncology technologies, particularly for hard-to-treat cancers.
Xenetic Biosciences (NASDAQ: XBIO) reported its second quarter 2022 results, highlighting a significant in-licensing deal that expands its oncology pipeline with a focus on DNase-based therapies. The company aims to advance its DNase program towards a Phase 1 study targeting pancreatic carcinoma and other advanced solid tumors. Financially, Xenetic ended the quarter with $14.9 million in cash but posted a net loss of approximately $2.7 million. R&D expenses surged by 296.1% due to investments in the new DNase platform.
FAQ
What is the current stock price of Xenetic Biosciences (XBIO)?
What is the market cap of Xenetic Biosciences (XBIO)?
